COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup.
Journal
Nature reviews. Nephrology
ISSN: 1759-507X
Titre abrégé: Nat Rev Nephrol
Pays: England
ID NLM: 101500081
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
accepted:
09
09
2020
pubmed:
17
10
2020
medline:
15
12
2020
entrez:
16
10
2020
Statut:
ppublish
Résumé
Kidney involvement in patients with coronavirus disease 2019 (COVID-19) is common, and can range from the presence of proteinuria and haematuria to acute kidney injury (AKI) requiring renal replacement therapy (RRT; also known as kidney replacement therapy). COVID-19-associated AKI (COVID-19 AKI) is associated with high mortality and serves as an independent risk factor for all-cause in-hospital death in patients with COVID-19. The pathophysiology and mechanisms of AKI in patients with COVID-19 have not been fully elucidated and seem to be multifactorial, in keeping with the pathophysiology of AKI in other patients who are critically ill. Little is known about the prevention and management of COVID-19 AKI. The emergence of regional 'surges' in COVID-19 cases can limit hospital resources, including dialysis availability and supplies; thus, careful daily assessment of available resources is needed. In this Consensus Statement, the Acute Disease Quality Initiative provides recommendations for the diagnosis, prevention and management of COVID-19 AKI based on current literature. We also make recommendations for areas of future research, which are aimed at improving understanding of the underlying processes and improving outcomes for patients with COVID-19 AKI.
Identifiants
pubmed: 33060844
doi: 10.1038/s41581-020-00356-5
pii: 10.1038/s41581-020-00356-5
pmc: PMC7561246
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Consensus Development Conference
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
747-764Commentaires et corrections
Type : ErratumIn
Références
Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
doi: 10.1056/NEJMoa2001017
Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061–1069 (2020).
pubmed: 32031570
pmcid: 7042881
Wang, L. et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am. J. Nephrol. 51, 343–348 (2020).
pubmed: 32229732
Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513, (2020).
pubmed: 32007143
pmcid: 32007143
Cheng, Y. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 97, 829–838, (2020).
pubmed: 32247631
pmcid: 7110296
Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).
pubmed: 32109013
pmcid: 32109013
Wu, J. et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. Clin. Infect. Dis. 71, 706–712 (2020).
pubmed: 32109279
Pei, G. et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J. Am. Soc. Nephrol. 31, 1157–1165 (2020).
pubmed: 32345702
Chen, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1091 (2020).
pubmed: 32217556
pmcid: 32217556
Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).
pubmed: 32171076
pmcid: 7270627
Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet. Respir. Med. 8, 475–481 (2020).
Cao, J. et al. Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa243 (2020).
doi: 10.1093/cid/ciaa243
pubmed: 33079200
pmcid: 7197602
Arentz, M. et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 323, 1612–1614 (2020).
pubmed: 32191259
pmcid: 7082763
Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 323, 2052–2059 (2020).
pubmed: 32320003
pmcid: 7177629
Argenziano, M. G. et al. Characterization and clinical course of 1000 patients with COVID-19 in New York: retrospective case series. BMJ https://doi.org/10.1101/2020.04.20.20072116 (2020).
Hirsch, J. S. et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 98, 209–218 (2020).
pubmed: 32416116
pmcid: 7229463
Mohamed, M. M. et al. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans. Kidney https://doi.org/10.34067/KID.0002652020 (2020).
Intensive Care National Audit and Research Centre. ICNARC report on COVID-19 in critical care Case Mix Programme Database, www.icnarc.org (2020).
Gupta, S. et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern. Med. https://doi.org/10.1001/jamainternmed.2020.3596 (2020).
doi: 10.1001/jamainternmed.2020.3596
pubmed: 33080002
Murugan, R. et al. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int. 77, 527–535 (2010).
pubmed: 20032961
Kellum, J. A., Bellomo, R. & Ronco, C. Acute dialysis quality initiative (ADQI): methodology. Int. J. Artif. Organs 31, 90–93 (2008).
pubmed: 18311725
Atkins, D. et al. Grading quality of evidence and strength of recommendations. BMJ 328, 1490 (2004).
pubmed: 15205295
Su, H. et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 98, 219–227 (2020).
pubmed: 32327202
pmcid: 7194105
Farkash, E. A., Wilson, A. M. & Jentzen, J. M. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J. Am. Soc. Nephrol. 31, 1683–1687 (2020).
pubmed: 32371536
Peleg, Y. et al. Acute kidney injury due to collapsing glomerulopathy following COVID-19 infection. Kidney Int. Rep. 5, 940–945 (2020).
Larsen, C. P., Bourne, T. D., Wilson, J. D., Saqqa, O. & Sharshir, M. A. Collapsing glomerulopathy in a patient with coronavirus disease 2019 (COVID-19). Kidney Int. Rep. 5, 935–939 (2020).
pubmed: 32292867
pmcid: 7142700
Kissling, S. et al. Collapsing glomerulopathy in a COVID-19 patient. Kidney Int. 98, 228–231 (2020).
pubmed: 32471639
pmcid: 7156952
Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841–845 (2010).
pubmed: 20647424
pmcid: 2980843
Rossi, G. M. et al. Kidney biopsy findings in a critically ill COVID-19 patient with dialysis-dependent acute kidney injury: a case against “SARS-CoV-2 nephropathy”. Kidney Int. Rep. 5, 1100–1105 (2020).
pubmed: 32426558
pmcid: 7230145
Schaller, T. et al. Postmortem examination of patients with COVID-19. JAMA 323, 2518–2520 (2020).
pubmed: 32437497
pmcid: 7243161
Santoriello, D. et al. Postmortem kidney pathology findings in patients with COVID-19. J. Am. Soc. Nephrol. 31, 2158–2167 (2020).
pubmed: 32727719
Puelles, V. G. et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590–592 (2020).
pubmed: 32402155
Braun, F. et al. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet 396, 597–598 (2020).
pubmed: 32818439
pmcid: 7431179
Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 383, 120–128 (2020).
pubmed: 32437596
Liu, J. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55, 102763 (2020).
pubmed: 7165294
pmcid: 7165294
Delanghe, J. R., Speeckaert, M. M. & De Buyzere, M. L. The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin. Chim. Acta 505, 192–193 (2020).
pubmed: 32220422
pmcid: 7102561
Othman, H. et al. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism. Biochem. Biophys. Res. Commun. 527, 702–708 (2020).
pubmed: 32410735
pmcid: 7221370
Chang, J. H. et al. Donor’s APOL1 risk genotype and “Second Hits” associated with de novo collapsing glomerulopathy in deceased donor kidney transplant recipients: a report of 5 cases. Am. J. Kidney Dis. 73, 134–139 (2019).
pubmed: 30054024
Velez, J. C. Q., Caza, T. & Larsen, C. P. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat. Rev. Nephrol. 16, 565–567 (2020).
pubmed: 32753739
Goldstein, S. L. et al. A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children. Kidney Int. 97, 580–588 (2020).
pubmed: 31980139
Noris, M., Benigni, A. & Remuzzi, G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 98, 314–322 (2020).
pubmed: 32461141
pmcid: 7246017
Tisoncik, J. R. et al. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76, 16–32 (2012).
pubmed: 22390970
pmcid: 3294426
Chien, J. Y., Hsueh, P. R., Cheng, W. C., Yu, C. J. & Yang, P. C. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology 11, 715–722 (2006).
pubmed: 17052299
pmcid: 7192207
Chu, K. H. et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int. 67, 698–705 (2005).
pubmed: 15673319
pmcid: 7112337
Min, C. K. et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci. Rep. 6, 25359 (2016).
pubmed: 27146253
pmcid: 4857172
Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664–679 (2016).
pubmed: 27076371
pmcid: 5448406
Spittler, A. et al. Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production. Clin. Infect. Dis. 31, 1338–1342 (2000).
pubmed: 11095999
Welch, H. K., Kellum, J. A. & Kane-Gill, S. L. Drug-associated acute kidney injury identified in the United States food and drug administration adverse event reporting system database. Pharmacotherapy 38, 785–793 (2018).
pubmed: 29883524
Ostermann, M. et al. Drug management in acute kidney disease — report of the acute disease quality initiative XVI meeting. Br. J. Clin. Pharmacol. 84, 396–403 (2018).
pubmed: 29023830
Cuadrado-Payan, E. et al. SARS-CoV-2 and influenza virus co-infection. Lancet 395, e84 (2020).
pubmed: 32423586
pmcid: 7200126
Koyner, J. L. & Murray, P. T. Mechanical ventilation and lung-kidney interactions. Clin. J. Am. Soc. Nephrol. 3, 562–570 (2008).
pubmed: 18256378
pmcid: 6631081
Dudoignon, E. et al. Activation of the renin-angiotensin-aldosterone system is associated with acute kidney injury in COVID-19. Anaesth. Crit. Care Pain Med. 39, 453–455 (2020).
pubmed: 32565254
pmcid: 7301818
Li, T. et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. Eur. J. Clin. Nutr. 74, 871–875 (2020).
pubmed: 32322046
Joannidis, M. et al. Lung-kidney interactions in critically ill patients: consensus report of the acute disease quality initiative (ADQI) 21 workgroup. Intensive Care Med. 46, 654–672 (2020).
pubmed: 31820034
Armutcu, F. Organ crosstalk: the potent roles of inflammation and fibrotic changes in the course of organ interactions. Inflamm. Res. 68, 825–839 (2019).
pubmed: 31327029
Jin, M. & Tong, Q. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg. Infect. Dis. 26, 1618–1620 (2020).
pubmed: 32197060
pmcid: 7323559
Sargiacomo, C., Sotgia, F. & Lisanti, M. P. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging 12, 6511–6517 (2020).
pubmed: 32229706
pmcid: 7202514
Spagnolo, P. et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir. Med. 8, 750–752 (2020).
pubmed: 32422177
pmcid: 7228737
Kashani, K. et al. Quality improvement goals for acute kidney injury. Clin. J. Am. Soc. Nephrol. 14, 941–953 (2019).
pubmed: 31101671
pmcid: 6556737
Intensive Care National Audit & Research Centre. https://www.icnarc.org (2020).
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2 (Suppl. 1), 1–138 (2012).
Al-Jaghbeer, M., Dealmeida, D., Bilderback, A., Ambrosino, R. & Kellum, J. A. Clinical decision support for in-hospital AKI. J. Am. Soc. Nephrol. 29, 654–660 (2018).
pubmed: 29097621
Hernandez-Arroyo, C. F., Varghese, V., Mohamed, M. M. B. & Velez, J. C. Q. Urinary sediment microscopy in acute kidney injury associated with COVID019. Kidney360 1, 819–823 (2020).
Husain Syed, F. et al. Acute kidney injury and urinary biomarkers in hospitalized patients with coronavirus disease-2019. Nephrol. Dial. Transplant. 35, 1271–1274 (2020).
pubmed: 32691068
pmcid: 7454800
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
pubmed: 31986264
pmcid: 31986264
Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 180, 934–943 (2020).
pubmed: 32167524
Argenziano, M. G. et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 369, m1996 (2020).
pubmed: 32471884
pmcid: 7256651
Cummings, M. J. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study. Lancet 395, 1763–1770 (2020).
pubmed: 32442528
pmcid: 7237188
Chen, Tao et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1295 (2020).
Nasr, S. H. & Kopp, J. B. COVID-19-associated collapsing glomerulopathy: an emerging entity. Kidney Int. Rep. 5, 759–761 (2020).
pubmed: 32368701
pmcid: 7196556
Rhodes, A. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit. Care Med. 45, 486–552 (2017).
pubmed: 28098591
Ostermann, M., Liu, K. & Kashani, K. Fluid management in acute kidney injury. Chest 156, 594–603 (2019).
pubmed: 31002784
Douglas, I. S. et al. Fluid response evaluation in sepsis hypotension and shock: a randomized clinical trial. Chest https://doi.org/10.1016/j.chest.2020.04.025 (2020).
doi: 10.1016/j.chest.2020.04.025
pubmed: 32353418
Brown, R. M. et al. Balanced crystalloids versus saline in sepsis. a secondary analysis of the SMART clinical trial. Am. J. Respir. Crit. Care Med. 200, 1487–1495 (2019).
pubmed: 31454263
pmcid: 6909845
Malbrain, M. et al. Intravenous fluid therapy in the perioperative and critical care setting: executive summary of the International Fluid Academy (IFA). Ann. Intensive Care 10, 64 (2020).
pubmed: 32449147
pmcid: 7245999
Self, W. H. et al. Balanced crystalloids versus saline in noncritically ill adults. N. Engl. J. Med. 378, 819–828 (2018).
pubmed: 29485926
pmcid: 5846618
Verma, B. et al. A multicentre randomised controlled pilot study of fluid resuscitation with saline or Plasma-Lyte 148 in critically ill patients. Crit. Care Resusc. 18, 205–212 (2016).
pubmed: 27604335
Semler, M. W. et al. Balanced crystalloids versus saline in critically ill adults. N. Engl. J. Med. 378, 829–839 (2018).
pubmed: 29485925
pmcid: 5846085
Antequera Martín, A. M. et al. Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children. Cochrane Database Syst. Rev. 7, Cd012247 (2019).
pubmed: 31334842
Zayed, Y. Z. M. et al. Balanced crystalloids versus isotonic saline in critically ill patients: systematic review and meta-analysis. J. Intensive Care 6, 51 (2018).
pubmed: 30140441
pmcid: 6098635
Zwager, C. L. et al. Why physiology will continue to guide the choice between balanced crystalloids and normal saline: a systematic review and meta-analysis. Crit. Care 23, 366 (2019).
pubmed: 31752973
pmcid: 6868741
Goldstein, S. L. et al. Electronic health record identification of nephrotoxin exposure and associated acute kidney injury. Pediatrics 132, e756–e767 (2013).
pubmed: 23940245
Goldstein, S. L. et al. A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury. Kidney Int. 90, 212–221 (2016).
pubmed: 27217196
Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 — preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007764 (2020).
doi: 10.1056/NEJMoa2007764
pubmed: 32991794
pmcid: 7556339
Dambha-Miller, H. et al. Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol. BJGP Open 4, bjgpopen20X101115 10.3399/bjgpopen20X101115 (2020).
Fosbøl, E. L. et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 324, 168–177 (2020).
pubmed: 32558877
Magrone, T., Magrone, M. & Jirillo, E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target — a perspective. Endocr. Metab. Immune Disord. Drug Targets 20, 807–811 (2020).
pubmed: 32338224
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323, 1824–1836 (2020).
pubmed: 32282022
Gattinoni, L. et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 46, 1099–1102 (2020).
pubmed: 32291463
Hering, R. et al. The effects of prone positioning on intraabdominal pressure and cardiovascular and renal function in patients with acute lung injury. Anesth. Analg. 92, 1226–1231 (2001).
pubmed: 11323351
Group, R. C. et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2021436 (2020).
doi: 10.1056/NEJMoa2021436
Arkin, N., Krishnan, K., Chang, M. G. & Bittner, E. A. Nutrition in critically ill patients with COVID-19: challenges and special considerations. Clin. Nutr. 39, 2327–2328 (2020).
pubmed: 32425291
pmcid: 7227546
Singer, P. et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin. Nutr. 38, 48–79 (2019).
pubmed: 30348463
Martindale, R. et al. Nutrition therapy in critically ill patients with coronavirus disease (COVID-19). JPEN J. Parenter. Enteral Nutr. https://doi.org/10.1002/jpen.1930 (2020).
doi: 10.1002/jpen.1930
pubmed: 32462719
pmcid: 7283713
Barazzoni, R. et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin. Nutr. 39, 1631–1638 (2020).
pubmed: 32305181
pmcid: 7138149
Ostermann, M., Macedo, E. & Oudemans-van Straaten, H. How to feed a patient with acute kidney injury. Intensive Care Med. 45, 1006–1008 (2019).
pubmed: 31037318
Barbar, S. D. et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N. Engl. J. Med. 379, 1431–1442 (2018).
pubmed: 30304656
Gaudry, S. et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet 395, 1506–1515 (2020).
pubmed: 32334654
Gaudry, S. et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N. Engl. J. Med. 375, 122–133 (2016).
pubmed: 27181456
Zarbock, A. et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA 315, 2190–2199 (2016).
pubmed: 27209269
Ostermann, M. et al. Patient selection and timing of continuous renal replacement therapy. Blood Purif. 42, 224–237 (2016).
Palevsky, P. M. et al. Intensity of renal support in critically ill patients with acute kidney injury. N. Engl. J. Med. 359, 7–20 (2008).
pubmed: 18492867
Bellomo, R. et al. Intensity of continuous renal-replacement therapy in critically ill patients. N. Engl. J. Med. 361, 1627–1638 (2009).
pubmed: 19846848
Vesconi, S. et al. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit. Care 13, R57 (2009).
pubmed: 19368724
pmcid: 2689504
Claure-Del Granado, R. et al. Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis. Clin. J. Am. Soc. Nephrol. 6, 467–475 (2011).
pubmed: 21115626
pmcid: 3082402
Joannidis, M. & Oudemans-van Straaten, H. M. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit. Care 11, 218 (2007).
pubmed: 17634148
pmcid: 2206533
Adapa, S. et al. COVID-19 and renal failure: challenges in the delivery of renal replacement therapy. J. Clin. Med. Res. 12, 276–285 (2020).
pubmed: 32489502
pmcid: 7239583
El Shamy, O., Sharma, S., Winston, J. & Uribarri, J. Peritoneal dialysis during the Coronavirus 2019 (COVID-19) pandemic: acute inpatient and maintenance outpatient experiences. Kidney Med. 2, 377–380 (2020).
pubmed: 32337505
pmcid: 7179486
Liu, L., Zhang, L., Liu, G. J. & Fu, P. Peritoneal dialysis for acute kidney injury. Cochrane Database Syst. Rev. 12, CD011457 (2017).
pubmed: 29199769
Srivatana, V. et al. Peritoneal dialysis for acute kidney injury treatment in the United States: brought to you by the COVID-19 pandemic. Kidney360 1, 410–415 (2020).
Parienti, J. J. et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA 299, 2413–2422 (2008).
pubmed: 18505951
Marik, P. E., Flemmer, M. & Harrison, W. The risk of catheter-related bloodstream infection with femoral venous catheters as compared to subclavian and internal jugular venous catheters: a systematic review of the literature and meta-analysis. Crit. Care Med. 40, 2479–2485 (2012).
pubmed: 22809915
Oliver, M. J., Edwards, L. J., Treleaven, D. J., Lambert, K. & Margetts, P. J. Randomized study of temporary hemodialysis catheters. Int. J. Artif. Organs 25, 40–44 (2002).
pubmed: 11853070
Nahum, J. et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw. Open 3, e2010478 (2020).
pubmed: 32469410
pmcid: 7260620
Iba, T. et al. The unique characteristics of COVID-19 coagulopathy. Crit. Care 24, 360 (2020).
pubmed: 32552865
pmcid: 7301352
Iba, T., Levy, J. H., Levi, M., Connors, J. M. & Thachil, J. Coagulopathy of coronavirus disease 2019. Crit. Care Med. 48, 1358–1364 (2020).
pubmed: 32467443
Helms, J. et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 46, 1089–1098 (2020).
pubmed: 32367170
Chua, H. R. et al. Ensuring sustainability of continuous kidney replacement therapy in the face of extraordinary demand: lessons from the COVID-19 pandemic. Am. J. Kidney Dis. 76, 392–400 (2020).
pubmed: 32505811
pmcid: 7272152
Lempert, K. D. & Kopp, J. B. Renal failure patients in disasters. Disaster Med. Public Health Prep. 13, 782–790 (2019).
pubmed: 31057134
pmcid: 6897549
Durvasula, R., Wellington, T., McNamara, E. & Watnick, S. COVID-19 and kidney failure in the acute care setting: our experience from Seattle. Am. J. Kidney Dis. 76, 4–6 (2020).
pubmed: 32276031
pmcid: 7141473
Nagatomo, M. et al. Peritoneal dialysis for COVID-19-associated acute kidney injury. Crit. Care 24, 309 (2020).
pubmed: 32513214
pmcid: 7276956
Alfano, G. et al. Peritoneal dialysis in the time of coronavirus disease 2019. Clin. Kidney J. 13, 265–268 (2020).
pubmed: 32699612
pmcid: 7367121
Ponce, D., Balbi, A. L., Durand, J. B., Moretta, G. & Divino-Filho, J. C. Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury. Clin. Kidney J. 13, 269–273 (2020).
pubmed: 32695319
pmcid: 7337686
Sourial, M. Y. et al. Urgent peritoneal dialysis in patients with COVID-19 and acute kidney injury: a single-center experience in a time of crisis in the United States. Am. J. Kidney Dis. 76, 401–406 (2020).
pubmed: 32534129
pmcid: 7287441
Griffin, K. M., Karas, M. G., Ivascu, N. S. & Lief, L. Hospital preparedness for COVID-19: a practical guide from a critical care perspective. Am. J. Respir. Crit. Care Med. 201, 1337–1344 (2020).
pubmed: 32298146
pmcid: 7258631
Jaber, S. et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet 392, 31–40 (2018).
pubmed: 29910040
Peacock, W. F. et al. Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase II, randomized, double-blind, placebo-controlled study (ENERGIZE). Acad. Emerg. Med. 27, 475–486 (2020).
pubmed: 32149451
pmcid: 7318712
Burgner, A., Ikizler, T. A. & Dwyer, J. P. COVID-19 and the inpatient dialysis unit: managing resources during contingency planning pre-crisis. Clin. J. Am. Soc. Nephrol. 15, 720–722 (2020).
pubmed: 32245780
Ronco, C. & Reis, T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat. Rev. Nephrol. 16, 308–310 (2020).
pubmed: 32273593
Ronco, C., Reis, T. & Husain-Syed, F. Management of acute kidney injury in patients with COVID-19. Lancet Respir. Med. https://doi.org/10.1016/S2213-2600(20)30229-0 (2020).
doi: 10.1016/S2213-2600(20)30229-0
pubmed: 32416769
pmcid: 7162620
Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46, 846–848 (2020).
pubmed: 32125452
Zhou, Z. et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27, 883–890 e882 (2020).
pubmed: 7196896
pmcid: 7196896
Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417–1418 (2020).
pubmed: 32325026
pmcid: 7172722
Joly, B. S., Siguret, V. & Veyradier, A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med. 46, 1603–1606 (2020).
pubmed: 32415314
Honore, P. M. et al. Cytokine removal in human septic shock: where are we and where are we going? Ann. Intensive Care 9, 56 (2019).
pubmed: 31089920
pmcid: 6517449
Dellinger, R. P. et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA 320, 1455–1463 (2018).
pubmed: 30304428
pmcid: 6233793
Koch, B. et al. Lectin affinity plasmapheresis for middle east respiratory syndrome-coronavirus and marburg virus glycoprotein elimination. Blood Purif. 46, 126–133 (2018).
pubmed: 29698959
pmcid: 6008873
Ankawi, G. et al. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Crit. Care 22, 262 (2018).
pubmed: 30360755
pmcid: 6202855
Gruda, M. C. et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb(R) sorbent porous polymer beads. PLoS One 13, e0191676 (2018).
pubmed: 29370247
pmcid: 5784931
Klein, D. J. et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 44, 2205–2212 (2018).
pubmed: 30470853
pmcid: 6280819
Cruz, D. N. et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301, 2445–2452 (2009).
pubmed: 19531784
Knaup, H. et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit. Care 22, 285 (2018).
pubmed: 30373638
pmcid: 6206942
Busund, R., Koukline, V., Utrobin, U. & Nedashkovsky, E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 28, 1434–1439 (2002).
pubmed: 12373468
Keith, P. et al. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit. Care 24, 128 (2020).
pubmed: 32241301
pmcid: 7117947
Villa, G. et al. Organ dysfunction during continuous veno-venous high cut-off hemodialysis in patients with septic acute kidney injury: a prospective observational study. PLoS One 12, e0172039 (2017).
pubmed: 28207795
pmcid: 5313216
Broman, M. E., Hansson, F., Vincent, J. L. & Bodelsson, M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS One 14, e0220444 (2019).
pubmed: 31369593
pmcid: 6675097
Kacar, C. K., Uzundere, O., Kandemir, D. & Yektas, A. Efficacy of HA330 hemoperfusion adsorbent in patients followed in the intensive care unit for septic shock and acute kidney injury and treated with continuous venovenous hemodiafiltration as renal replacement therapy. Blood Purif. 49, 448–456 (2020).
pubmed: 31991412
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT04361526 (2020).
US National Library of Medicine. US National Library of Medicine https://www.clinicaltrials.gov/ct2/show/NCT04324528 . (2020).